We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.39 | -0.43% | 91.23 | 91.00 | 91.62 | 91.72 | 89.63 | 91.38 | 1,682,358 | 16:40:00 |
From Apr 2019 to Apr 2024
By Olivia Bugault
Sanofi SA said Thursday that the European Commission has granted a marketing authorization for Supemtek, a recombinant vaccine for the prevention of influenza in adults aged 18 or more.
"The authorization is based on clinical data demonstrating safety, immunogenicity and efficacy of Supemtek in two Phase-3 randomized controlled trials," the pharmaceutical giant said.
The first European launches should happen for the 2022-2023 influenza season, but there will be a possibility to have doses available in the 2021/2022 season in some countries, Sanofi said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
November 19, 2020 02:16 ET (07:16 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
